Colistin is the last-line antibiotic against Gram-negative pathogens. Here we identify an FDA-approved drug, Otilonium bromide (Ob), which restores the activity of colistin against colistin-resistant Gram-negative bacteria in vitro and in a mouse infection model. Ob also reduces the colistin dosage required for effective treatment of infections caused by colistin-susceptible bacteria, thereby reducing the toxicity of the drug regimen. Furthermore, Ob acts synergistically with colistin in eradicating multidrug-tolerant persisters of Gram-negative bacteria in vitro. Functional studies and microscopy assays confirm that the synergistic antimicrobial effect exhibited by the Ob and colistin involves permeabilizing the bacterial cell membrane, dissipating proton motive force and suppressing efflux pumps, resulting in membrane damages, cytosol leakage and eventually bacterial cell death. Our findings suggest that Ob is a colistin adjuvant which can restore the clinical value of colistin in combating life-threatening, multidrug resistant Gram-negative pathogens.
Infectious diseases caused by multidrug-resistant (MDR) pathogens have become a serious and rapidly worsening public health problem worldwide1. According to a previous review on antimicrobial resistance, infections caused by MDR strains may cause over 10 million deaths per year by 2050 if no proactive measures are taken to slow down the rapidly increasing trend of drug resistance2. The emergence of the resistance determinants blaNDM-1 and blaKPC-2, which are highly transmissible among strains of various species and known to encode carbapenem resistance, causes further reduction in the number of therapeutic options that remain3,4,5. Colistin, also called polymyxin E, is a polycationic antimicrobial peptide regarded as one of the last-resort antibiotics that can be used to treat infections caused by MDR Gram-negative strains, especially carbapenem-resistant Enterobacteriaceae (CRE), due to its high efficacy and low resistance rate6. Colistin exhibits electrostatic binding affinity to the negatively charged lipid A in the lipopolysaccharide (LPS) molecules located on the surface of Gram-negative bacteria, leading to the membrane damage and leakage of cellular contents, and hence bacterial cell death7. However, the clinical value of colistin is limited by its nephrotoxicity and neurotoxicity8. In addition, colistin resistance is increasingly being reported. Mutations in the phoPQ and pmrAB genes, which encode two different component systems, as well as the mgrB gene mutations, were reported to be associated with over-expression of lipid A modification enzymes such as EptA, as well as reduced affinity of Lipid A to polymyxins9,10. In recent years, a new mechanism of colistin resistance mediated by the plasmid-encoded enzyme MCR-1, which catalyzes the modification of lipid A, has been reported worldwide11,12,13,14,15,16. Worse still, the mobilizable colistin resistance gene mcr-1 has increasingly been acquired by CRE strains carrying the blaKPC17, blaNDM18, and blaVIM genes19, rendering those strains able to evolve into real “superbugs” which are resistant to almost all known antimicrobial agents. Therefore, novel strategies that can help overcome colistin resistance in Gram-negative pathogens especially CRE are urgently needed. Compared with the time-consuming and expensive process of developing new antibiotics, identifying colistin adjuvants that can restore colistin activity and reduce the treatment dosage is a more effective and eco-friendly strategy to restore or even enhance the clinical value of colistin as a last-line antibiotic20,21.
Otilonium bromide (Ob, IUPAC: N,Ndiethyl-N-methyl-2-[(4-benzoyl)oxy]ethanaminium), an FDA-approved antispasmodic drug, is extensively applied for treatment of patients suffering from irritable bowel syndrome (IBS)22. It has been shown that Ob could block the L- and T-type Ca2+ channels and muscarinic and tachykinin receptors in the smooth muscle23. Ob is poorly absorbed by human cells so that there is no significant side effect reported for its clinical use24. Although the antimicrobial effects of Ob on Clostridioides difficile25 and Staphylococcus aureus26 have been reported in previous studies, the potential of using Ob for treatment of infections caused by Gram-negative pathogens has not been explored. In this study, we observed a strong synergistic antimicrobial effect when Ob and colistin were used together for inhibiting the growth of both colistin-resistant and susceptible Gram-negative strains in vitro. The drug combination was found to be particularly effective in treatment of infections caused by colistin-resistant CRE in in vivo experiments. The mechanisms underlying this synergistic antimicrobial effect were investigated in this work. The discovery of Ob as a new and safe colistin adjuvant provides a novel option for combating infections caused by MDR Gram-negative pathogens.
Results and discussion
Ob potentiates colistin activity against both colistin-susceptible and colistin-resistant bacteria in vitro
In this study, E. coli J53 strain carrying a natural mcr-1-bearing IncI2 plasmid (33 kb, KX711706.1) was used to screen and identify colistin adjuvants which could enhance the antibacterial activity of colistin27. Using the checkerboard dilution assay, Ob was found to act synergistically with colistin (FICI = 0.25), conferring a 32-fold reduction in colistin MIC (from 8 µg/ml to 0.28 µg/ml) when 20 µg/ml of Ob was used in the susceptibility test. This degree of reduction in MIC is sufficient to bring the MIC of the majority of the test strains to a level below the clinical breakpoint (2 µg/ml, according to CLSI 2020) (Fig. 1a). Ob also acts synergistically with colistin against colistin-susceptible E. coli J53 strain (FICI ≤ 0.141), reducing the MIC from 1 µg/ml to ≤0.016 µg/ml when 10 µg/ml of Ob was used (Fig. 1b). We next tested if such synergistic antimicrobial effect was also observable in other Gram-negative strains and found that the colistin and Ob combination exhibited synergistic antimicrobial effect on both colistin-susceptible and colistin-resistant strains of various Gram-negative pathogens. This finding suggests that Ob is a potential broad-spectrum colistin adjuvant that can act on all major Gram-negative bacterial pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, and Salmonella spp. (Supplementary Table 1).
To further evaluate the synergistic antimicrobial effect of Ob and colistin on colistin-resistant and colistin-susceptible E. coli, time-kill curves were constructed for the test strains growing in the exponential phase (Fig. 2). The growth of colistin-resistant E. coli could only be inhibited by colistin at 32 µg/ml and higher concentrations. However, the effective bactericidal concentration of colistin could be reduced to 8 µg/ml in the presence of 20 µg/ml of Ob. For colistin-susceptible E. coli, 8 µg/ml of colistin was required to eradicate the strains; in the presence of 20 µg/ml of Ob, however, 1 µg/ml colistin was sufficient to achieve complete eradication of the organism (Fig. 2). These data suggest that Ob indeed enhances the bactericidal activity of colistin against both colistin-resistant and colistin-susceptible E. coli dramatically, implying that the mechanism is not limited to inhibition of the colistin resistance mechanism.
The strong synergistic antimicrobial effect exhibited by Ob and colistin was visualized by the LIVE/DEAD cell viability assay. Fluorescence microscopy was performed to quantify the number of live and dead cells and determine the degree of reduction in colistin concentration in the drug combination required for effective eradication of the test organisms. Almost all mcr-1-bearing E. coli strains were alive upon treatment with saline, 8 µg/ml of colistin alone or 20 µg/ml of Ob alone. In the presence of 20 µg/ml of Ob, 4 µg/ml of colistin could eradicate >97% of organisms (Supplementary Fig. 1).
Ob acts synergistically with colistin to eliminate clinical colistin-resistant E. coli strains in mouse infection model
The in vivo antimicrobial effect of the Ob and colistin combination was further tested in the mouse sepsis model, with results showing that Ob could re-sensitize colistin-resistant CRE to colistin. Our data showed that all mice died within 36 h upon treatment with saline, colistin alone, or Ob alone. Treatment with a combination of Ob and colistin could successfully rescue 80% of the animals at 48 hpi, suggesting that Ob exhibits synergistic antimicrobial effect with colistin in treatment of infections caused by colistin-resistant CRE strains (Fig. 3).
Ob and colistin combination eliminates tolerant Gram-negative bacterial cells in vitro
All bacterial populations, including those of non-antibiotic resistant strains, are known to harbor drug-tolerant sub-population that do not respond to antimicrobial actions of antibiotics. Such antibiotic tolerant sub-population are now known to be the culprit of a wide range of chronic and recurrent infections, especially among immunocompromised patients28,29. We therefore tested the bactericidal effect of the Ob and colistin combination on antibiotic tolerant bacterial sub-population. Ob was found to strongly enhance the efficacy of colistin in killing the starvation-induced bacterial tolerant cells of colistin-resistant and colistin-susceptible E. coli and A. baumannii strains. Compared to the initial population size of ~108 CFU/mL of mcr-1-bearing E. coli strain re-suspended in saline, the size of the viable population remained at a high level of 5 × 105 CFU/ml upon treatment with colistin at 32 µg/ml for 24 h. However, the entire drug-tolerant population was effectively eradicated by 2 µg/ml of colistin in the presence of 20 µg/ml of Ob in 24-h treatment. Ob could also act synergistically with colistin on the tolerant sub-population of colistin-susceptible E. coli and A. baumannii strains by reducing the concentration of colistin required to completely eradicate such sub-population to 1 µg/ml in a 24-h treatment (Fig. 4). These data suggest that Ob has high potential to be developed into a therapeutic agent for eradication of bacterial tolerant sub-population.
Ob enhances the ability of colistin to cause membrane disruption
Colistin exhibits high bactericidal efficacy against Gram-negative pathogens through specifically binding to the negatively charged phosphate group of lipid A in LPS in the cell membrane of Gram-negative bacteria, causing an increase in cell membrane permeability and leakage of cellular contents30. The mechanism of colistin resistance in Gram-negative bacteria mainly involves modification of lipid A, which renders colistin binding ineffective31. We therefore hypothesized that Ob might restore the ability of colistin to disrupt bacterial cell membrane. To test this hypothesis, we first visualized the morphological changes in colistin-resistant E. coli upon treatment with sub-MIC of colistin (8 µg/ml), Ob (20 µg/ml), and the combination of both, using SEM. No morphological changes were observed when mcr-1-bearing E. coli was treated with sub-MIC of Ob or colistin. When treated with 4 µg/ml of colistin and 20 µg/ml of Ob, the bacterial envelope was completely disrupted and leakage of the cytosol could be observed, along with shrinkage of the cell membrane. Treatment with 20 µg/ml Ob, 8 µg/ml of colistin resulted in more severe disruption of cell membrane, suggesting that the presence of Ob could restore the killing effect of colistin on colistin-resistant E. coli (Fig. 5). To further confirm this theory, SYTOX Green staining analysis was employed to assess the membrane permeability of colistin-resistant E. coli before and after treatment with the colistin and Ob combination. SYTOX Green is a green-fluorescence nucleotide dye used to test membrane permeability and membrane integrity32. Green fluorescence can be detected by fluorescence spectrometer when bacterial cell integrity is destroyed and membrane permeability increases. Consistently, the data showed that Ob and colistin could each cause a significant increase in fluorescence in mcr-1-bearing E. coli, indicating that both drugs could cause increase in bacterial cell membrane permeability (Fig. 6a, b). The ability of Ob in enhancing membrane permeability was lower than colistin. As expected, treatment with the Ob and colistin combination caused a drastic increase in membrane permeability, suggesting that the effective bactericidal concentration of colistin can be reduced in the presence of Ob (Fig. 6c). Furthermore, microscopy imaging of mcr-1-bearing E. coli stained with SYTOX depicted a much more dramatic increase in fluorescence when the strain was treated with a combination of 20 µg/ml Ob and 8 µg/ml colistin, when compared to monotreatment with colistin or Ob at the same concentration (Fig. 6d).
Previous studies demonstrated that electrostatic interaction between colistin and the negatively charged LPS caused displacement of divalent ions (Ca2+ and Mg2+) from the phospholipids and hence disruption of the bacterial cell membrane33,34. Divalent ions act as a cross-linker that allows networking of LPS molecules, so that the membrane becomes structurally stable, tightly packed, and only selectively permeable35. The effect of divalent ions on the antibacterial activity of Ob and colistin was further investigated. Addition of Mg2+ and Ca2+, particularly Ca2+, could suppress the activity of colistin and the Ob and colistin combination on both colistin-resistant and susceptible E. coli. We also determined the activity of Ob and colistin on P. aeruginosa, with results showing that supplementation of calcium ions could also suppress the bactericidal effect of colistin and the drug combination on this pathogen (Supplementary Fig. 2).
Ob acts as a membrane proton motive force dissipator (PMF)
Proton motive force (PMF; ∆P) is an electrochemical gradient of protons generated by the electron transport chain in bacteria, which acts by extruding protons out of the cells. PMF, which is necessary for ATP synthesis and transport of various solutes36, is the sum of two parameters: the electric or membrane potential (∆φ) and the transmembrane proton gradient (∆pH). To further investigate the nature of damage inflicted by Ob and colistin on bacterial cell membrane, the membrane potential of colistin-resistant E. coli was determined using 3,3-dipropylthiadicarbocyanine iodide (DiSC3(5)). Valinomycin, a K+ transporter, was used as the positive control which can cause complete dissipation of bacterial membrane potential. Upon dissipation of membrane potential, DiSC3(5) cannot be anchored onto the bacterial membrane of mcr-1-bearing E. coli and would be released to the medium, resulting in a marked increase in fluorescence intensity. Ob was found to act as a strong membrane potential dissipator which caused a PMF dissipation rate even higher than that of valinomycin. The combined use of Ob and colistin caused extremely rapid dissipation of PMF in colistin-resistant E. coli (Fig. 7a–d). Consistently, microscopy image of mcr-1-bearing E. coli could be stained with DiSC3(5), whereas treatment with 20 µg/ml Ob caused membrane potential dissipation and the release of the dye to the medium (Fig. 7e). We also investigated the effect of Ob and colistin on the membrane potential of colistin-susceptible E. coli J53. Ob itself could also cause dissipation of membrane potential of the colistin susceptible strains, indicating that the PMF dissipation effect of Ob does not involve neutralizing the effect of the mcr-1 gene product (Supplementary Fig. 3).
Ob and colistin combination suppresses efflux activities
Since PMF is required for driving efflux activities, the effect of the combination of Ob and colistin on efflux activities was determined using the Nile Red efflux assay37. Nile red is a substrate of various efflux pumps which becomes strongly fluorescent upon partitioning into the bacterial membrane, and could be pumped out of the cell immediately38. Carbonyl cyanide m-chlorophenylhydrazone (CCCP), an PMF dissipator, was employed as a positive control to inactivate efflux pumps effectively39. Monotreatment with either 20 µg/ml Ob or 8 µg/ml colistin caused rapid reduction in Nile red export in mcr-1-bearing E. coli J53, with a reduction rate even higher than that recorded for 10 µM CCCP (Fig. 8a, b). The combined use of Ob and colistin exerted an even stronger inhibitory effect on Nile red efflux, confirming that Ob and colistin act synergistically in inhibiting Nile red efflux (Fig. 8c). Addition of 50 mM glucose could energized the efflux pump and trigger the efflux again, so that the inactivation effect of CCCP was effectively counteracted and Nile red could again be pumped out to the medium immediately. In comparison, the energization effect of glucose on de-energized cells subjected to treatment with Ob, colistin and the combination of both, was lower than that recorded in CCCP-treated cells. The synergistic effect of Ob and colistin on inactivation of Nile red efflux was also observed in colistin-susceptible E. coli J53, with results confirming that the inhibitory effect on efflux pump exerted by Ob and colistin does not involve interaction with the mcr-1 gene product (Fig. 8d).
Ob suppresses bacterial motility
As a previous study reported that flagellar formation was dependent on PMF and that flagellar motor rotation was driven by PMF, we further determined the effect of Ob on bacterial motility40. P. seruginosa exhibited swarming motility on semisolid surface; such motility was dependent upon a functional flagella41,42. As shown in Fig. 9, the migration distance of PAO1 inoculated onto a semisolid agar plate containing Ob was found to decrease in a dose-dependent manner after overnight incubation. Gramicidin, an ionophore acting as PMF dissipator, was used as the positive control. Furthermore, a significant increase in migration distance of PAO1 treated with 40 µM Ob supplemented with 10 mM calcium ions was observed, suggesting that 10 mM calcium ions could effectively suppress the inhibitory effect of Ob on bacterial swarming.
It has been reported that the combination of colistin and adjuvant compounds that could restore colistin activity offered a promising strategy to treat infections caused by colistin-resistant pathogens21. Although previous studies have recommended Ob in treatment of IBS by using it as a calcium channel blocker43, its potential in treating bacterial infections has not been extensively studied. Ob was shown to exhibit antimicrobial effect on Staphylococcus aureus, Clostridium difficile, and A. baumannii through causing membrane damages26,44. In this study, although Ob itself is only weakly bactericidal, it exhibits strong synergistic effect when used in combination with colistin in treatment of infection caused by both colistin-resistant and susceptible Gram-negative pathogens. Ob is an FDA-approved drug without major side effects in human24, and can effectively reduce the treatment dosage of colistin and hence the toxicity of colistin on mammalian cells. It should be noted that the neurotoxicity and nephrotoxicity of colistin is the key factor limiting its clinical value45.
In the mechanistic study, Ob was found to act synergistically with colistin to permeabilize bacterial cell membrane, dissipate PMF, inhibit multidrug efflux pump function and suppress bacterial motility. The increased membrane permeability induced by the combination of Ob and colistin allows for self-promoted uptake of the colistin molecule to further enhance its damaging effect46. The action of Ob and colistin could both be suppressed by high concentration of divalent ions (especially Ca2+ ions), suggesting that they could each displace the membrane-stabilizing divalent ions, resulting in an increase in membrane permeability. Furthermore, Ob is an amphipathic compound that contains both a hydrophilic quaternary amine and a hydrophobic long carbon chain. These functional groups enable it to partition into the phospholipid bilayer of the membrane and cause membrane damage47,48.
The displacement of the membrane-stabilizing magnesium and calcium ions by Ob and colistin also results in disruption of the electron transport chain and hence further dissipation of proton motive force. Ob could also act as a calcium channel blocker to inhibit the transportation of the membrane-stabilizing calcium ions. Dissipation of PMF upon treatment by Ob and colistin is associated with membrane depolarization and dysfunction, as well as metabolic perturbation. The metabolic status of the bacterial cell is known to be severely impacted by the actions of antimicrobial agents49. Since PMF is required to drive efflux activities, PMF dissipation results in suppression of efflux and rapid accumulation of drugs and hence further cellular damages. Suppression of bacterial motility also leads to increased exposure of bacterial cells to Ob and colistin, thereby enhancing their antimicrobial efficacy (Fig. 10)50.
The clinical value of colistin has been undermined by its cytotoxicity and the emergence of resistant strains. Development of colistin adjuvant is the most effective strategy to overcome the public health threat associated with the emergence of colistin-resistant Gram-negative pathogens, especially the colistin-resistant CRE strains. In this study, we identified Ob as a promising colistin adjuvant that can restore the bactericidal effect of colistin by allowing it to eradicate colistin-resistant Gram-negative strains both in vitro and in mouse infection model. The activity of colistin against colistin-susceptible Gram-negative strains can also be enhanced by Ob, so that a much smaller amount of the drug can be used in clinical treatment. Furthermore, Ob exhibits synergistic bactericidal effect with colistin when tested on starvation-induced tolerant Gram-negative bacterial cells in vitro. The Ob and colistin combination were found to cause membrane permeabilization, dissipation of PMF, and inhibition of efflux activities, leading to extensive membrane damage and eventually cell death. Based on these observations, we believe that Ob, which is already a FDA-approved drug, is a reliable colistin adjuvant which can fully restore and even enhance the clinical value of colistin. This drug combination may be readily developed into a novel therapeutic option for treatment of infections caused by multidrug-resistant Gram-negative pathogens.
Bacterial strains and reagents
All strains used in this study are listed in Supplementary Table 1. Strains were grown in Luria-Bertani (LB) broth or LB agar plates at 37 °C overnight. All chemicals used in this study were obtained from Sigma-Aldrich.
Antimicrobial susceptibility tests
Determination of the minimum inhibitory concentration (MIC) of colistin in the presence and absence of Ob was conducted using a broth dilution method51. The results were analyzed according to the Clinical & Laboratory Standards Institute guideline52. Briefly, colistin and Ob were two-fold diluted with cation-adjusted MH broth and mixed with equal volume of bacterial suspensions (1.5 × 106 colony-forming units (CFUs)/ml) in 96-well microtiter plate. After 16 h incubation at 37 °C, MIC values were determined as the lowest concentration of colistin and Ob that prevents the visible growth of strains. All experiments were performed in triplicate.
To further analyze the synergistic antimicrobial effect of colistin and Ob, a checkerboard assay was performed according to methods described previously27. Briefly, Ob and colistin were two-fold serially diluted with 150 μl of MH broth to create an 8 × 12 matrix. Bacteria suspension (2 × 106 CFUs/ml) were inoculated into the media and incubated at 37 °C for 16 h. The absorbance at 600 nm were determined using SpectraMax ABS Microplate Reader (Molecular Devices, United States). The fractional inhibitory concentration index (FICI) was calculated using the formula as follows: FIC index = (MIC of colistin in combination with Ob)/(MIC of colistin alone) + (MIC of Ob in combination with colistin)/(MIC of Ob alone). Synergy was defined as an FIC index ≤0.5. All experiments were performed in triplicate.
Determination of the synergistic antimicrobial effect of the Ob and colistin drug combination
A time-dependent killing curve was constructed to evaluate the synergistic antimicrobial effect of Ob when it was used in combination with colistin to inhibit colistin susceptible and resistant E. coli strains53. Briefly, E. coli in the exponential phase was treated with a series of concentrations of colistin, Ob, and various combinations of both. Viable cells at each time point were counted in triplicate and killing curves were drawn using GraphPad Prism 8.0 (San Diego, CA, USA).
Evaluation of the bactericidal effect of Ob and colistin on colistin-resistant E. coli by LIVE/DEAD staining
The bactericidal effect of the combination of Ob and colistin on colistin-resistant E. coli was investigated using the LIVE/DEAD BacLight Bacterial Viability Kit (L1702)54. Briefly, mcr-1-bearing E. coli J53 in the exponential phase was treated with Ob, colistin, and different combinations of both at 37 °C for 2 h. The culture was then centrifuged, and the cell pellet was washed twice with sterile PBS, followed by re-suspension in 300 µL PBS. Each microliter of bacterial suspension was stained with three microliters of dye at room temperature in dark for 15 min. After staining, the bacterial cells were washed twice with PBS and re-suspended in 100 µL PBS. Two microliters of the bacterial suspension were used for imaging by fluorescence microscopy (Nikon Eclipse Ti2 fluorescence microscope, Nikon, Tokyo, Japan). Quantitative analysis was conducted in triplicates by counting the live and dead bacterial cells54.
Visualization of the synergistic killing effect of Ob and colistin on colistin-resistant E. coli by scanning electronic microscopy (SEM)
SEM imaging was employed to examine the change in cellular morphology of colistin-resistant E. coli incubated with the combination of Ob and colistin according to the procedure described previously, with some modifications55. Briefly, MCR-1 producing E. coli J53 at the exponential phase was incubated with Ob, colistin, and different combinations of both for 2 h. After treatment, the bacterial cell pellets were washed twice with PBS, followed by fixation with 2.5% glutaraldehyde for 1 h at 4 °C. The fixed cells were then dehydrated with 50% ethanol and 100% ethanol. The cellular morphology was observed using a scanning electron microscope (Tescan VEGA3).
Cationic ion assays
The effect of different divalent cations, including CaCl2 and MgCl2, on the antimicrobial effect of the combination of colistin and Ob against colistin susceptible and colistin-resistant E. coli was evaluated through determination of MIC of the test agents in the presence of the cations based on the Clinical & Laboratory Standards Institute guideline56,57.
The effect of Ob on the swarming motility of Pseudomonas aeruginosa was investigated as described previously, with some modifications58. The medium for the motility assay was tryptic soy broth containing 0.5% of agar and different concentrations of Ob. 10 μg/ml of gramicidin was also included to compare the effect of Ob. The effect of calcium ions on the swarming phenotype of the strains was also evaluated by the addition of 10 mM CaCl2 during the assay.
Membrane permeability test
The bacterial membrane permeability of colistin-resistant and colistin-susceptible E. coli was determined using SYTOX Green as described previously59, with slight modifications. Overnight culture of mcr-1-bearing E. coli J53 was diluted 100-fold in 3 mL of fresh LB and incubated at 37 °C until the exponential phase was reached. The cultures were then incubated with different concentrations of Ob at 37 °C for 3 h. After incubation, the culture was centrifuged and washed twice with PBS. The pellets were re-suspended in PBS to prepare the bacterial suspension (OD600 = 0.2). SYTOX Green (1 µM) was added to 1 mL bacterial suspension and cultured in dark for 10 min. The fluorescence intensity of the test samples was monitored using the SpectraMax® iD3 Multi-Mode Microplate Reader (Molecular Devices, Austria) with an excitation and emission wavelength of 488 and 523 nm, respectively.
Membrane potential assays using 3,3′-dipropylthiadicarbocyanine iodide [DiSC3(5)]
Bacterial membrane potential was determined using the voltage-sensitive dye [DiSC3(5)] as described previously27. Briefly, the stained cells were treated with different concentrations of Ob alone, colistin alone, and different combinations of both. The fluorescence level of the sample was measured for a period of 30 min using a SpectraMax® iD3 Multi-Mode Microplate Reader. 1 µM valinomycin was added as the positive control. The stained bacterial cells were observed using fluorescence microscopy.
Assessment of efflux inhibitory effect of Ob and colistin using Nile Red
The inhibitory effect of Ob and colistin on the activities of efflux pumps was evaluated by performing a Nile Red efflux assay38. Briefly, bacterial cells (OD600 = 1.0) treated with different concentrations of colistin, Ob, and various combinations of both were stained with 5 µM Nile red for 3 h at 37 °C. Upon staining, bacterial cells were washed and re-suspended with phosphate-buffered saline (PBS) containing 1 mM MgCl2 and subjected to the indicated treatment. Fluorometric measurements were carried out on black polystyrene microtiter plates for another 2.8 min using a microplate reader, after which the cell suspension was treated with 50 mM glucose. Changes in fluorescence level of the sample were then further monitored for 20 min using a Microplate Reader.
Mouse infection model
The antimicrobial effect of the combination of Ob and colistin against colistin-resistant carbapenem-resistant E. coli strain CoREC5 was also tested in a mouse infection model according to a method described previously, with some modifications27. In this experiment, male NIH mice were divided into four groups (five mice per group) and infected intraperitoneally with 6.0 × 108 CFU E. coli CoREC5. At 1 h post infection (hpi), the mice were then injected intraperitoneally with 8 mg/kg of colistin, 10 mg/kg of Ob, and a combination of both, respectively, every 12 h for 48 h. Four untreated animals were included as control. All animal experiments were approved by the Animal Subjects Ethics Sub-Committee of City University of Hong Kong.
Statistics and reproducibility
Statistical analysis was performed using GraphPad Prism 8. All data from at least triplicates are shown as mean ± SD. Unpaired t test were used to calculate P values (*P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001).
All data are available within the paper and the Supplementary Information. All data are available from the corresponding authors upon reasonable request. The source data can be found at https://figshare.com/articles/dataset/Ob_numerical_source_data_xlsx/19736755.
Yelin, I. & Kishony, R. Antibiotic resistance. Cell 172, 1136–1136 (2018).
O’Neill, J. Tackling Drug-resistant Infections Globally: Final Report and Recommendations (2016).
van Duin, D. & Doi, Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 8, 460–469 (2017).
Stoesser, N. et al. Genomic epidemiology of complex, multispecies, plasmid-borne bla KPC carbapenemase in Enterobacterales in the United Kingdom from 2009 to 2014. Antimicrob. Agents Chemother. 64, e02244-02219 (2020).
Walsh, T. R., Weeks, J., Livermore, D. M. & Toleman, M. A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. 11, 355–362 (2011).
Sun, J., Zhang, H., Liu, Y.-H. & Feng, Y. Towards understanding MCR-like colistin resistance. Trends Microbiol. 26, 794–808 (2018).
Biswas, S., Brunel, J.-M., Dubus, J.-C., Reynaud-Gaubert, M. & Rolain, J.-M. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti-infective Ther. 10, 917–934 (2012).
Lim, L. M. et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy: J. Hum. Pharmacol. Drug Ther. 30, 1279–1291 (2010).
Adams, M. D. et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob. Agents Chemother. 53, 3628–3634 (2009).
Giani, T. et al. Large nosocomial outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae traced to clonal expansion of an mgrB deletion mutant. J. Clin. Microbiol. 53, 3341–3344 (2015).
Liu, Y.-Y. et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect. Dis. 16, 161–168 (2016).
Perrin-Guyomard, A. et al. Prevalence of mcr-1 in commensal Escherichia coli from French livestock, 2007 to 2014. Eurosurveillance 21, 30135 (2016).
Zurfuh, K. et al. Occurrence of the plasmid-borne mcr-1 colistin resistance gene in extended-spectrum-β-lactamase-producing Enterobacteriaceae in river water and imported vegetable samples in Switzerland. Antimicrob. Agents Chemother. 60, 2594–2595 (2016).
Malhotra-Kumar, S. et al. Colistin-resistant Escherichia coli harbouring mcr-1 isolated from food animals in Hanoi, Vietnam. Lancet Infect. Dis. 16, 286–287 (2016).
Tse, H. & Yuen, K.-Y. Dissemination of the mcr-1 colistin resistance gene. Lancet Infect. Dis. 16, 145–146 (2016).
Poirel, L. et al. Genetic features of MCR-1-producing colistin-resistant Escherichia coli isolates in South Africa. Antimicrob. Agents Chemother. 60, 4394–4397 (2016).
Falgenhauer, L. et al. Colistin resistance gene mcr-1 in extended-spectrum β-lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. Lancet Infect. Dis. 16, 282–283 (2016).
Yao, X., Doi, Y., Zeng, L., Lv, L. & Liu, J.-H. Carbapenem-resistant and colistin-resistant Escherichia coli co-producing NDM-9 and MCR-1. Lancet Infect. Dis. 16, 288–289 (2016).
Poirel, L., Kieffer, N., Liassine, N., Thanh, D. & Nordmann, P. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of Escherichia coli. Lancet Infect. Dis. 16, 281 (2016).
Douafer, H., Andrieu, V., Phanstiel, O. IV & Brunel, J. M. Antibiotic adjuvants: make antibiotics great again! J. Med. Chem. 62, 8665–8681 (2019).
Tyers, M. & Wright, G. D. Drug combinations: a strategy to extend the life of antibiotics in the 21st century. Nat. Rev. Microbiol. 17, 141–155 (2019).
Evangelista, S., Traini, C. & Vannucchi, M. G. Otilonium Bromide: a drug with a complex mechanism of action. Curr. Pharm. Des. 24, 1772–1779 (2018).
Traini, C., Evangelista, S., Girod, V., Faussone-Pellegrini, M. S. & Vannucchi, M. G. Repeated otilonium bromide administration prevents neurotransmitter changes in colon of rats underwent to wrap restraint stress. J. Cell. Mol. Med. 21, 735–745 (2017).
Triantafillidis, J. K. & Malgarinos, G. Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review. Clin. Exp. Gastroenterol. 7, 75 (2014).
Shrivastava, A. & Mittal, A. A mini review on characteristics and analytical methods of otilonium bromide. Crit. Rev. Anal. Chem. https://doi.org/10.1080/10408347.2021.1913983 (2021).
Zhou, L. et al. Repurposing antispasmodic agent otilonium bromide for treatment of Staphylococcus aureus infections. Front. Microbiol. 11, 1720 (2020).
Xu, C. et al. Imidazole type antifungal drugs are effective colistin adjuvants that resensitize colistin‐resistant Enterobacteriaceae. Adv. Therapeutics 3, 2000084 (2020).
Fauvart, M., De Groote, V. N. & Michiels, J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J. Med. Microbiol. 60, 699–709 (2011).
Narayanaswamy, V. P. et al. Novel glycopolymer eradicates antibiotic-and CCCP-induced persister cells in Pseudomonas aeruginosa. Front. Microbiol. 9, 1724 (2018).
El-Sayed Ahmed, M. A. E.-G. et al. Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019). Emerg. Microbes Infect. 9, 868–885 (2020).
Poirel, L., Jayol, A. & Nordmann, P. Polymyxins: antibacterial activity, susceptibility testing, and resistance mechanisms encoded by plasmids or chromosomes. Clin. Microbiol. Rev. 30, 557–596 (2017).
Vaessen, E., Timmermans, R., Tempelaars, M., Schutyser, M. & den Besten, H. Reversibility of membrane permeabilization upon pulsed electric field treatment in Lactobacillus plantarum WCFS1. Sci. Rep. 9, 1–11 (2019).
Sabnis, A. et al. Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane. Elife 10, e65836 (2021).
Kempf, I. et al. What do we know about resistance to colistin in Enterobacteriaceae in avian and pig production in Europe? Int. J. Antimicrob. Agents 42, 379–383 (2013).
Raetz, C. R. & Whitfield, C. Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71, 635–700 (2002).
Mitchell, P. Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. Biochim. Biophys. Acta-Bioenerg. 1807, 1507–1538 (2011).
Li, X.-Z., Plésiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337–418 (2015).
Bohnert, J. A., Karamian, B. & Nikaido, H. Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates. Antimicrob. Agents Chemother. 54, 3770–3775 (2010).
Baron, S. A. & Rolain, J.-M. Efflux pump inhibitor CCCP to rescue colistin susceptibility in mcr-1 plasmid-mediated colistin-resistant strains and Gram-negative bacteria. J. Antimicrob. Chemother. 73, 1862–1871 (2018).
Minamino, T. & Namba, K. Distinct roles of the FliI ATPase and proton motive force in bacterial flagellar protein export. Nature 451, 485–488 (2008).
Hou, L., Debru, A., Chen, Q., Bao, Q. & Li, K. AmrZ regulates swarming motility through cyclic di-GMP-dependent motility inhibition and controlling Pel polysaccharide production in Pseudomonas aeruginosa PA14. Front. Microbiol. 10, 1847 (2019).
Yeung, A. T. et al. Swarming of Pseudomonas aeruginosa is controlled by a broad spectrum of transcriptional regulators, including MetR. J. Bacteriol. 191, 5592–5602 (2009).
Strege, P. R. et al. T-type Ca2+ channel modulation by otilonium bromide. Am. J. Physiol.-Gastrointest. Liver Physiol. 298, G706–G713 (2010).
Knauf, G. A. et al. Exploring the antimicrobial action of quaternary amines against Acinetobacter baumannii. MBio 9, e02394-02317 (2018).
Velkov, T. et al. Polymyxins for CNS infections: pharmacology and neurotoxicity. Pharmacol. Therapeut. 181, 85–90 (2018).
Trimble, M. J., Mlynárčik, P., Kolář, M. & Hancock, R. E. Polymyxin: alternative mechanisms of action and resistance. Cold Spring Harb. Perspect. Med. 6, a025288 (2016).
Andersen, C., Holland, I. & Jacq, A. Verapamil, a Ca2+ channel inhibitor acts as a local anesthetic and induces the sigma E dependent extra-cytoplasmic stress response in E. coli. Biochim. Biophys. Acta-Biomembr. 1758, 1587–1595 (2006).
Shi, B. & Tien, H. T. Action of calcium channel and beta-adrenergic blocking agents in bilayer lipid membranes. Biochim. Biophys. Acta-Biomembr. 859, 125–134 (1986).
Lopatkin, A. J. et al. Bacterial metabolic state more accurately predicts antibiotic lethality than growth rate. Nat. Microbiol. 4, 2109–2117 (2019).
Stabryla, L. M. et al. Role of bacterial motility in differential resistance mechanisms of silver nanoparticles and silver ions. Nat. Nanotechnol. 16, 996–1003 (2021).
Xu, C. et al. Imidazole type antifungal drugs are effective colistin adjuvants that resensitize colistin-resistant Enterobacteriaceae. Adv. Therapeutics. 3, 2000084 (2020).
In, C. Performance Standards for Antimicrobial Susceptibility Testing (Clinical and Laboratory Standards Institute, 2018).
Liu, Y. et al. Metformin restores tetracyclines susceptibility against multidrug resistant bacteria. Adv. Sci. 7, 1902227 (2020).
Yang, Q. et al. Balancing mcr-1 expression and bacterial survival is a delicate equilibrium between essential cellular defence mechanisms. Nat. Commun. 8, 2054 (2017).
Chhibber, S. et al. A novel approach for combating Klebsiella pneumoniae biofilm using histidine functionalized silver nanoparticles. Front. Microbiol. 8, 1104 (2017).
Song, M. et al. A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens. Nat. Microbiol. 5, 1040–1050 (2020).
Song, M. et al. Plant natural flavonoids against multidrug resistant pathogens. Adv. Sci. 8, 2100749 (2021).
Inoue, T., Shingaki, R. & Fukui, K. Inhibition of swarming motility of Pseudomonas aeruginosa by branched-chain fatty acids. FEMS Microbiol. Lett. 281, 81–86 (2008).
Sochacki, K. A., Barns, K. J., Bucki, R. & Weisshaar, J. C. Real-time attack on single Escherichia coli cells by the human antimicrobial peptide LL-37. Proc. Natl Acad. Sci. USA 108, E77–E81 (2011).
This research was supported by the Research Impact Fund (R5011-18F) from the Research Grant Council of Hong Kong Government.
The authors declare no competing interests.
Peer review information
Communications Biology thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editors: Cesar de la Fuente and Christina Karlsson Rosenthal. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Xu, C., Liu, C., Chen, K. et al. Otilonium bromide boosts antimicrobial activities of colistin against Gram-negative pathogens and their persisters. Commun Biol 5, 613 (2022). https://doi.org/10.1038/s42003-022-03561-z